FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia

On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33‐positive acute myeloid leukemia (AML) in patients 2 years of age and older. GO is a CD33‐directed antibody drug conj...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Norsworthy, Kelly J., Ko, Chia‐Wen, Lee, Jee Eun, Liu, Jiang, John, Christy S., Przepiorka, Donna, Farrell, Ann T., Pazdur, Richard
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2018
Matèries:
Regulatory Issues: FDA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192608/
https://ncbi.nlm.nih.gov/pubmed/29650683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0604
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars